Active, not recruitingPhase 1NCT05308654
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- ABBV-453(drug)
- Enrollment
- 34 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (21)
- Stanford University School of Med /ID# 242809, Stanford, California, United States
- Sylvester Comprehensive Cancer Center /ID# 243417, Miami, Florida, United States
- Tulane University School of Medicine /ID# 244854, New Orleans, Louisiana, United States
- American Oncology Partners of Maryland /ID# 244858, Bethesda, Maryland, United States
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 242754, Ann Arbor, Michigan, United States
- Mayo Clinic - Rochester /ID# 242844, Rochester, Minnesota, United States
- Memorial Sloan Kettering Cancer Center /ID# 243503, New York, New York, United States
- Atrium Health Levine Cancer Institute /ID# 243420, Charlotte, North Carolina, United States
- Duke Univ Med Ctr /ID# 242808, Durham, North Carolina, United States
- Wake Forest Baptist Health /ID# 244252, Winston-Salem, North Carolina, United States
- University of Pennsylvania /ID# 242842, Philadelphia, Pennsylvania, United States
- Vanderbilt Ingram Cancer Center /ID# 242810, Nashville, Tennessee, United States
- Liverpool Hospital /ID# 244826, Liverpool, New South Wales, Australia
- St. Vincent's Private Hospital Melbourne /ID# 262631, Fitzroy, Victoria, Australia
- St Vincent's Hospital Melbourne /ID# 244827, Fitzroy Melbourne, Victoria, Australia
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05308654 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGPHASE3NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Regeneron Pharmaceuticals
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.